Nasdaq:IRDPublished
Opus Genetics Announces First Participant Dosed in Phase 1/2 Clinical Trial of OPGx-RDH12 Gene Therapy for Rare Inherited Childhood Blindness
First participant dosed with OPGx-RDH12, an investigational gene therapy designed to address the underlying genetic cause of RDH12-associated Leber congenital amaurosis (RDH12-LCA) Milestone advances Opus Genetics' third gene therapy program into clinical development, following…
